Status | Study |
Withdrawn |
Study Name: The Plasma Large-Volume Exchange RCT Condition: Purpura, Thrombotic Thrombocytopenic Hemolytic Uremic Syndrome Date: 2011-09-09 Interventions: Procedure: Plasma Exchange Plasma exchange is a blood purification technique that removes plasma from th |
Recruiting |
Study Name: Influence of Extracorporeal Circulation During Cardiac Surgery on the Development of Postoperative Thrombotic Thrombocytopenic Purpura (TTP) Condition: Cardiac Surgery Date: 2011-02-18 |
Recruiting |
Study Name: Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome) Condition: Thrombotic Thrombocytopenic Purpura Congenital Date: 2010-12-06 Interventions: Other: Observation No interventions planned: treatment of patients at the discretion of the treating/res |
Completed |
Study Name: Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP) Condition: Thrombotic Thrombocytopenic Purpura Date: 2010-06-25 Interventions: Biological: anti-vWF Nanobody |
Recruiting |
Study Name: Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) Condition: Thrombotic Thrombocytopenic Purpura Date: 2009-08-04 Interventions: Drug: Danazol Danazol 600 mg PO will be initiated with plasma exchange and corticosteroids at the time o |
Recruiting |
Study Name: The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP) Condition: Thrombotic Thrombocytopenic Purpura (TTP) Date: 2009-07-09 Interventions: Drug: Rituximab Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infus |
Completed |
Study Name: Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Condition: Thrombotic Thrombocytopenic Purpura Date: 2009-05-22 Interventions: Drug: rituximab Patients will be treated according to the recommendations of the Reference Centre for th |
Terminated |
Study Name: Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP) Condition: Thrombotic Thrombocytopenic Purpura Date: 2008-11-26 Interventions: Drug: Rituximab Dose of 375 mg |
Terminated |
Study Name: Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy Condition: Thrombotic Microangiopathy Thrombotic Thrombocytopenic Purpura Date: 2008-07-30 Interventions: Drug: ARC 1779 Placebo ARC1779 |
Active, not recruiting |
Study Name: Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) Condition: Thrombotic Thrombocytopenic Purpura Date: 2008-07-09 Interventions: Drug: Cyclosporine 2-3 mg/kg o |